Basel Medical Group Ltd

AI-generated fair value estimate for this company.

Method: Asset-based (tangible book value with distress discount): total shareholders' equity $5.05M (FY2026 Q2 balance sheet: total assets $15.56M less total liabilities $10.52M) on 1.57M shares outstanding post 1-for-12 reverse split = $3.22 book value/share; applied ~0.65x multiple to book to reflect going-concern/execution risk, yielding ~$2.10/share.

Reasoning: Basel Medical is a loss-making Singapore clinic operator (TTM net loss -$7.81M on $11.46M revenue), with equity down and liabilities up quarter over quarter and no history of positive free cash flow, so a going-concern-adjusted book-value approach is more defensible than a DCF; note the company also announced exploratory, unconsummated negotiations for a ~$1B bitcoin share-swap acquisition (vastly larger than its ~$7M market cap), which was excluded from the valuation as speculative and unquantifiable, but flags elevated event/dilution risk.